Balaji Prasad
Stock Analyst at Barclays
(3.49)
# 887
Out of 5,124 analysts
147
Total ratings
49.19%
Success rate
4.79%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $4.50 | +455.56% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $14.52 | -24.24% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $21.00 | +14.29% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $14.58 | -38.27% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $165.50 | +20.85% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $25.20 | -24.60% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $64.62 | -7.15% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $127.42 | +91.49% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $8.21 | +192.33% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $53.07 | -58.55% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $644.61 | -19.33% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $34.69 | -25.05% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $190.44 | -15.98% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.08 | +20.74% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $5.12 | +251.56% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.52 | +121.24% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $2.14 | +227.10% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $4.50
Upside: +455.56%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $14.52
Upside: -24.24%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $21.00
Upside: +14.29%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $14.58
Upside: -38.27%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $165.50
Upside: +20.85%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $25.20
Upside: -24.60%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $64.62
Upside: -7.15%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $127.42
Upside: +91.49%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $8.21
Upside: +192.33%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $53.07
Upside: -58.55%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $644.61
Upside: -19.33%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $34.69
Upside: -25.05%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $190.44
Upside: -15.98%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.08
Upside: +20.74%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $5.12
Upside: +251.56%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.52
Upside: +121.24%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $2.14
Upside: +227.10%